GlassScriptPhysician profile
Clayton Douglas Borg
NPI 1427060581
$14,377.95
in general payments reported to CMS, 2019-2025
33 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $1,206 · 2021: $1,438 · 2022: $2,381 · 2023: $2,512 · 2024: $2,467 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,646 · Education: $99.99 · Travel and Lodging: $32.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,645.56 |
| Education | $99.99 |
| Travel and Lodging | $32.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,849.37 | 2019-2025 | Leqvio |
| Abbott Laboratories | $2,292.84 | 2019-2025 | Mitraclip |
| Edwards Lifesciences Corporation | $1,209.77 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $1,008.13 | 2020-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $944.29 | 2019-2025 | Jardiance |
| Pfizer INC. | $942.84 | 2019-2024 | |
| Boston Scientific Corporation | $812.87 | 2019-2024 | Sentinel, Watchman Access System |
| Amgen INC. | $644.23 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $623.86 | 2019-2024 | Xarelto |
| Medtronic, INC. | $518.67 | 2021-2024 | Corevalve Evolut R |
| Heartflow, INC. | $320.05 | 2023-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $295.40 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $268.17 | 2019-2024 | |
| Ge Healthcare | $224.04 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $209.58 | 2022-2025 | Amvuttra, Onpattro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186.52 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abiomed | $144.96 | 2019-2023 | Impella |
| Astellas Pharma US INC | $144.92 | 2019 | |
| Lantheus Medical Imaging, INC. | $131.50 | 2022-2025 | Definity |
| Esperion Therapeutics, INC. | $113.16 | 2020-2021 | |
| Irhythm Technologies, INC. | $88.90 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $73.32 | 2023-2025 | Verquvo |
| Bridgebio Pharma, INC. | $64.94 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.82 | 2019-2023 | Lifevest |
| Akcea Therapeutics, INC. | $38.84 | 2019 | |
| United Therapeutics Corporation | $38.34 | 2024 | Remodulin, Orenitram, Tyvaso |
| Scpharmaceuticals INC. | $35.68 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $28.87 | 2023-2024 | Inpefa |
| Cardiva Medical, INC. | $21.98 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Regeneron Healthcare Solutions, INC. | $16.45 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.77 | 2024 | Arcalyst |
| Cmp Pharma, INC. | $14.21 | 2023 | Carospir |
| Glaxosmithkline, LLC. | $13.66 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Borg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.